Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361555 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 789
- Enrollment target
NCT01361555: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01361555 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 789 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (493% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01361555, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 789 participants
- Enrollment target
Study Summary
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
Interventions
- DRUG BMS-820836
- DRUG Placebo matching with BMS-820836
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Why NCT01361555 stopped before completion
NCT01361555 is an interventional study that assigns participants to a tested intervention. The registered 789 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (493% higher).
The record links to 0 conditions, and to 2 interventions - of which BMS-820836 is the first listed.
NCT01361555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01361555 about?
NCT01361555 is a clinical study titled "Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression". The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
What is the current status of trial NCT01361555?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 789 participants. The study started on 2011-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01361555?
The interventions under investigation include: BMS-820836 (DRUG), Placebo matching with BMS-820836 (DRUG).
Who is sponsoring clinical trial NCT01361555?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01361555's enrollment target sits among peer trials
789 40th of 2000 higher than 1,961 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia